Ideaya Biosciences IncIDYA
ASignal's systematic analysis rates IDYA as Neutral.
Reflects the latest available analysis · analyzed Aug 29, 2026
The case on IDYA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $828.96M in total cash
- Low debt-to-equity ratio of 0.02x indicating minimal leverage risk
- High current and quick ratios (10.45x, 10.21x) signaling strong liquidity
- MACD above signal line with positive histogram expansion
- Price above 20-day and 50-day moving averages indicating uptrend
- Negative profit, operating, and gross margins indicating significant losses
- Forward P/E of -9.76x and negative EV/EBITDA of -15.08x suggest unprofitability
- No Reddit mentions, indicating low retail investor interest
- RSI at 67.18 — approaching overbought territory
- Lack of revenue and earnings growth data (N/A), limiting fundamental visibility
See the full verdict on IDYA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes IDYA
Most investors never get a second opinion, let alone several. ASignal runs IDYA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.